second line treatment
Showing 1 - 25 of >10,000
Relevance and Efficiency of SecOnd Line Workup for Uveitis
Not yet recruiting
- Uveitis
- second line investigations for uveitis etiological workup
- (no location specified)
Oct 25, 2023
OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)
Not yet recruiting
- OR Regimen Refractory Marginal Zone Lymphoma
- obrutinib, rituximab
- (no location specified)
Nov 12, 2023
Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)
Not yet recruiting
- Second Line Treatment of Gastric Cancer
- Camrelizumab
- +2 more
- (no location specified)
Dec 20, 2022
Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)
Recruiting
- Cervical Cancer Recurrent
- RC48 + Tislelizumab
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 25, 2023
Mesotheliomas Pleural Trial in Amsterdam (Pembrolizumab, Lenvatinib)
Recruiting
- Mesotheliomas Pleural
-
Amsterdam, Noord-Holland, NetherlandsAntoni van Leeuwenhoekziekenhuis (NKI-AVL)
Jan 13, 2023
HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)
Recruiting
- HER2-positive Gastric Cancer
- Immunotherapy
- Disitamab Vedotin combined with fruquintinib and Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2023
Colorectal Cancer Trial in Changsha (fruquintinib and FOLFIRI)
Not yet recruiting
- Colorectal Cancer
- fruquintinib and FOLFIRI
-
Changsha, Hunan, ChinaHunan Cancer hospital
Apr 24, 2023
NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)
Completed
- Non-Small Cell Lung Cancer
- Brain Neoplasms
- bevacizumab
- +2 more
- (no location specified)
Dec 9, 2022
Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with
Enrolling by invitation
- Gastric / Gastroesophageal Junction Adenocarcinoma
- envafolimab and lenvatinib combined with paclitaxel-albumin
-
Shanghai, Shanghai, ChinaFudan University Cancer Hospital
Sep 3, 2023
Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,
Not yet recruiting
- Metastatic Gastric Adenocarcinoma
- +2 more
- nal-IRI /Experimental
- +2 more
- (no location specified)
Jun 25, 2023
Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)
Recruiting
- Gastrointestinal Stromal Tumors
- Apatinib Mesylate
- Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
-
Changsha, Hunan, ChinaXiangya Hospital, Central South University
Mar 1, 2023
Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)
Recruiting
- Immunotherapy
- Second-line Treatment
-
Guizhou, ZunYi, ChinaThe Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023
Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- (no location specified)
Nov 27, 2022
Progression-free Survival Trial (Sovalteinib Solutumab Tegeo)
Not yet recruiting
- Progression-free Survival
- Sovalteinib Solutumab Tegeo
- (no location specified)
Jul 24, 2023
Intrahepatic Cholangiocarcinoma Trial in Tianjin (Regorafenib and HAIC, FOLFOX)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Regorafenib and HAIC
- FOLFOX
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Sep 7, 2022
HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- trastuzumab, bevacizumab with paclitaxel (triple combination)
- (no location specified)
Dec 6, 2022
Metastatic Pancreatic Adenocarcinoma Trial (Avelumab and Pepinemab)
Recruiting
- Metastatic Pancreatic Adenocarcinoma
- Avelumab and Pepinemab
-
Rochester, New YorkUniversity of Rochester Medical Center
Jan 19, 2023
Stomach Tumors Trial in Wuhan (Fruquintinib, Sintilimab)
Not yet recruiting
- Stomach Neoplasms
-
Wuhan, Hubei, ChinaWuhan Union Hospital, China
Nov 22, 2022
Adrenocortical Carcinoma Trial (Camrelizumab)
Recruiting
- Adrenocortical Carcinoma
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Dec 16, 2022
Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)
Not yet recruiting
- Recurrent Liver Cancer After Liver Transplantation
- Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
- (no location specified)
Apr 17, 2023
Smoking Cessation, Harm Reduction Trial in Charlotte, Raleigh (Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product)
Not yet recruiting
- Smoking Cessation
- Harm Reduction
- Nicoderm
- +4 more
-
Charlotte, North Carolina
- +1 more
Oct 17, 2023
Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)
Not yet recruiting
- Gastrointestinal Stromal Tumors
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2023